VAXXEL: Vaxxel raises EUR 1.2m to fund the development of its intranasal bivalent vaccine candidate against bronchiolitis and viral pneumonia

Press Release
Lyon (FR) - 18 March 2022, 8:00 am CET Vaxxel , a French start-up developing vaccines against respiratory viral infections, announces it has raised €1.2 million funding to support

Related Keywords

France ,French ,Kostenloser Wertpapierhandel ,Transgene Euronext ,Virpath Lyon ,Denis Cavert ,Laboratory Of The University Claude Bernard ,Ministry Of Higher Education ,Health Investor Network ,Manuel Rosa Calatrava Co ,European Business Angels Network ,University Of Laval Qu ,Pulsalys Technology Transfer Office ,Respiratory Syncytial Virus ,Family Offices ,Business Angels ,Angels Sant ,Femmes Business Angels ,University Claude Bernard ,Manuel Rosa Calatrava Co Director ,Guy Boivin ,Lyon Ing ,Higher Education ,European Business Angel ,European Business Angels ,Business Angels Europe ,Investor Network ,Vaxxel ,Raises ,Fund ,Development ,Intranasal ,Bivalent ,Vaccine ,Candidate ,Against ,Bronchiolitis ,Viral ,Pneumonia ,